Angiogenesis in Glioblastoma—Treatment Approaches
Glioblastoma, the most common primary malignant brain tumor in adults, carries a poor prognosis, with a median survival of just 15 months, significantly impacting patients’ quality of life. The aggressive growth of these highly vascularized tumors relies heavily on angiogenesis, driven primarily by...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-03-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/14/6/407 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850203994745470976 |
|---|---|
| author | Agnieszka Nowacka Maciej Śniegocki Wojciech Smuczyński Dominika Bożiłow Ewa Ziółkowska |
| author_facet | Agnieszka Nowacka Maciej Śniegocki Wojciech Smuczyński Dominika Bożiłow Ewa Ziółkowska |
| author_sort | Agnieszka Nowacka |
| collection | DOAJ |
| description | Glioblastoma, the most common primary malignant brain tumor in adults, carries a poor prognosis, with a median survival of just 15 months, significantly impacting patients’ quality of life. The aggressive growth of these highly vascularized tumors relies heavily on angiogenesis, driven primarily by vascular endothelial growth factor-A. Therefore, VEGF signaling pathway has become a prime therapeutic target in GBM treatment over the past decade. While anti-angiogenic treatment showed promise, agents like bevacizumab have ultimately failed to improve overall survival. This highlights the presence of compensatory angiogenic mechanisms that bypass VEGF inhibition, necessitating further investigation into resistance mechanisms and the development of more effective therapeutic strategies. This review examined the current landscape of anti-angiogenic agents for GBM, analyzed the mechanisms driving resistance to these therapies, and explored potential strategies for enhancing their effectiveness. |
| format | Article |
| id | doaj-art-8a2d80e6b73b48b084470acc87ad22b9 |
| institution | OA Journals |
| issn | 2073-4409 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj-art-8a2d80e6b73b48b084470acc87ad22b92025-08-20T02:11:22ZengMDPI AGCells2073-44092025-03-0114640710.3390/cells14060407Angiogenesis in Glioblastoma—Treatment ApproachesAgnieszka Nowacka0Maciej Śniegocki1Wojciech Smuczyński2Dominika Bożiłow3Ewa Ziółkowska4Department of Neurosurgery, Nicolas Copernicus University in Toruń, Collegium Medicum in Bydgoszcz, ul. Curie Skłodowskiej 9, 85-094 Bydgoszcz, PolandDepartment of Neurosurgery, Nicolas Copernicus University in Toruń, Collegium Medicum in Bydgoszcz, ul. Curie Skłodowskiej 9, 85-094 Bydgoszcz, PolandDepartment of Physiotherapy, Nicolas Copernicus University in Toruń, Collegium Medicum in Bydgoszcz, ul. Techników 3, 85-801 Bydgoszcz, PolandAnaesthesiology and Intensive Care Clinical Ward, The 10th Military Research Hospital and Polyclinic, ul. Powstańców Warszawy 5, 85-681 Bydgoszcz, PolandDepartment of Pediatrics, Washington University School of Medicine, St. Louis, MO 63110, USAGlioblastoma, the most common primary malignant brain tumor in adults, carries a poor prognosis, with a median survival of just 15 months, significantly impacting patients’ quality of life. The aggressive growth of these highly vascularized tumors relies heavily on angiogenesis, driven primarily by vascular endothelial growth factor-A. Therefore, VEGF signaling pathway has become a prime therapeutic target in GBM treatment over the past decade. While anti-angiogenic treatment showed promise, agents like bevacizumab have ultimately failed to improve overall survival. This highlights the presence of compensatory angiogenic mechanisms that bypass VEGF inhibition, necessitating further investigation into resistance mechanisms and the development of more effective therapeutic strategies. This review examined the current landscape of anti-angiogenic agents for GBM, analyzed the mechanisms driving resistance to these therapies, and explored potential strategies for enhancing their effectiveness.https://www.mdpi.com/2073-4409/14/6/407glioblastomaGBMangiogenesisVEGFbevacizumabanti-angiogenic therapy |
| spellingShingle | Agnieszka Nowacka Maciej Śniegocki Wojciech Smuczyński Dominika Bożiłow Ewa Ziółkowska Angiogenesis in Glioblastoma—Treatment Approaches Cells glioblastoma GBM angiogenesis VEGF bevacizumab anti-angiogenic therapy |
| title | Angiogenesis in Glioblastoma—Treatment Approaches |
| title_full | Angiogenesis in Glioblastoma—Treatment Approaches |
| title_fullStr | Angiogenesis in Glioblastoma—Treatment Approaches |
| title_full_unstemmed | Angiogenesis in Glioblastoma—Treatment Approaches |
| title_short | Angiogenesis in Glioblastoma—Treatment Approaches |
| title_sort | angiogenesis in glioblastoma treatment approaches |
| topic | glioblastoma GBM angiogenesis VEGF bevacizumab anti-angiogenic therapy |
| url | https://www.mdpi.com/2073-4409/14/6/407 |
| work_keys_str_mv | AT agnieszkanowacka angiogenesisinglioblastomatreatmentapproaches AT maciejsniegocki angiogenesisinglioblastomatreatmentapproaches AT wojciechsmuczynski angiogenesisinglioblastomatreatmentapproaches AT dominikaboziłow angiogenesisinglioblastomatreatmentapproaches AT ewaziołkowska angiogenesisinglioblastomatreatmentapproaches |